NHIP Gene Methylation Detection for ASD Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic interventions for autism spectrum disorders (ASD) are primarily behaviorally directed or symptom-based pharmacological treatments, with no preventive alternatives available, and existing methods to identify ASD risk genes lack coverage of structurally and epigenetically variable regions of the human genome.
Innovation Solution
A method for determining the risk of an offspring developing ASD by detecting the expression and/or DNA methylation of the neuronal hypoxia inducible, placental associated (NHIP) gene in biological samples, where decreased expression and/or methylation indicates an increased risk, and administering a vitamin to mothers with decreased NHIP gene activity to prevent ASD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If array-based methods are used to identify ASD risk genes, then the identification process can be performed, but coverage of structurally and epigenetically variable regions of the human genome is lacking
Solution Approach 1:
The patent changes the detection parameter from array-based hybridization to sequencing-based detection of DNA methylation patterns and structural variants. This allows comprehensive coverage of structurally and epigenetically variable regions including the 22q13.33 locus, transforming the method's ability to detect previously inaccessible genomic features while maintaining identifiability of ASD risk genes
2Reliability
If therapeutic interventions are applied after diagnosis, then symptom-based treatment can be provided, but preventive alternatives are not available
Solution Approach 1:
The patent enables preliminary identification of ASD risk through detection of DNA methylation patterns and structural variants in placental tissue before birth. By establishing the diagnosis prenatally rather than after symptom manifestation, the method creates a window for early intervention and prevents the time loss associated with post-diagnosis treatment initiation
3Loss of information
If complex genetics interacting with perinatal environment are considered, then a more comprehensive understanding of ASD etiology is achieved, but identification of common genetic risk becomes complicated
Solution Approach 1:
The patent uses placental DNA methylation patterns as an intermediary biomarker that reflects both genetic predisposition and perinatal environmental influences. This intermediary provides a measurable signature that integrates complex gene-environment interactions into a detectable pattern, simplifying the identification of common genetic risk while preserving information about etiological complexity
Data Source
AI summary
Described are methods for identifying an ASD risk gene, NHIP, and methods for determining the risk of an offspring for developing an ASD. A common structural variant disrupting the proximity of NHIP to a fetal brain enhancer was associated with NHIP expression and methylation levels and ASD risk, demonstrating a common genetic influence. NHIP is a novel environmentally-responsive ASD risk gene relevant to brain development in a previously under characterized region of the human genome.